Molnuva Capsule
Molnupiravir
200mg
NIPRO JMI Pharma Limited
| Pack size | 8's pack |
|---|---|
| Unite Price | 40.00 BDT |
Indications
Molnuva Capsule is used for:
Indicated for treatment of mild to moderate coronavirus disease 2019 (COVID-19) in adults with a positive SARS-COV-2 diagnostic test and who have at least one risk factor for developing severe illness. Such risk factors include obesity, older age (>60 years), diabetes mellitus, or heart disease.
Adult Dose
Adults
The recommended dose is 800 mg (four 200 mg capsules) taken orally every 12 hours for 5 days.
Hepatic Impairment
No dose adjustment is required for patients with hepatic impairment
Child Dose
Renal Dose
Renal Impairment
No dose adjustment is required for patients with renal impairment
Administration
Can be taken with or without food.
Contra Indications
Hypersensitivity to the active substance or to any of the excipients
Precautions
Pregnancy-Lactation
Pregnancy
There are no data from the use of Molnupiravir in pregnant women. Studies in animals have shown reproductive toxicity.
Molnupiravir is not recommended during pregnancy. Women of childbearing potential should use effective contraception for the duration of treatment and for 4 days after the last dose of molnupiravir.
Breastfeeding
It is unknown whether molnupiravir or any of the components of molnupiravir are present in human milk, affect human milk production, or have effect on the breastfed infant. Animal lactation studies with molnupiravir have not been conducted.
Based on the potential for adverse reactions on the infant from Lagevrio, breast-feeding is not recommended during treatment and for 4 days after the last dose of Lagevrio.
Interactions
Side Effects
Side effects of Molnupiravir :
The most common adverse reactions (≥1% of subjects) reported during treatment and during 14 days after the last dose were
diarrhoea (3%), nausea (2%), dizziness (1%) and headache (1%) all of which were Grade 1 (mild) or Grade 2 (moderate).
Mode of Action
Molnupiravir is a prodrug that is metabolised to the ribonucleoside analogue N-hydroxycytidine (NHC) which distributes into cells where it is phosphorylated to form the pharmacologically active ribonucleoside triphosphate (NHC-TP). NHC-TP acts by a mechanism known as viral error catastrophe. NHC-TP incorporation into viral RNA by the viral RNA polymerase, results in an accumulation of errors in the viral genome leading to inhibition of replication.
Note
Molnuva 200mg Capsule generic name is Molnupiravir. Molnuva 200mg Capsule is manufactured by NIPRO JMI Pharma LimitedMolnuva is availble in all over Bangladesh.
Mes BD drug index information on Molnuva Capsule is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.